465 related articles for article (PubMed ID: 14617769)
1. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes.
Bartosch B; Bukh J; Meunier JC; Granier C; Engle RE; Blackwelder WC; Emerson SU; Cosset FL; Purcell RH
Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14199-204. PubMed ID: 14617769
[TBL] [Abstract][Full Text] [Related]
2. Murine antibodies against E2 and hypervariable region 1 cross-reactively capture hepatitis C virus.
Esumi M; Ahmed M; Zhou YH; Takahashi H; Shikata T
Virology; 1998 Nov; 251(1):158-64. PubMed ID: 9813211
[TBL] [Abstract][Full Text] [Related]
3. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1.
Meunier JC; Engle RE; Faulk K; Zhao M; Bartosch B; Alter H; Emerson SU; Cosset FL; Purcell RH; Bukh J
Proc Natl Acad Sci U S A; 2005 Mar; 102(12):4560-5. PubMed ID: 15767578
[TBL] [Abstract][Full Text] [Related]
4. Antibodies directed to envelope proteins of hepatitis C virus outside of hypervariable region 1.
Lechner S; Rispeter K; Meisel H; Kraas W; Jung G; Roggendorf M; Zibert A
Virology; 1998 Apr; 243(2):313-21. PubMed ID: 9568031
[TBL] [Abstract][Full Text] [Related]
5. New neutralizing antibody epitopes in hepatitis C virus envelope glycoproteins are revealed by dissecting peptide recognition profiles.
Kachko A; Kochneva G; Sivolobova G; Grazhdantseva A; Lupan T; Zubkova I; Wells F; Merchlinsky M; Williams O; Watanabe H; Ivanova A; Shvalov A; Loktev V; Netesov S; Major ME
Vaccine; 2011 Dec; 30(1):69-77. PubMed ID: 22041300
[TBL] [Abstract][Full Text] [Related]
6. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
Vietheer PT; Boo I; Drummer HE; Netter HJ
Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
[TBL] [Abstract][Full Text] [Related]
7. Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
Mancini N; Carletti S; Perotti M; Romanò L; Craxì RD; Craxì A; Zanetti AR; Clementi M; Burioni R
J Med Virol; 2006 Oct; 78(10):1304-11. PubMed ID: 16927283
[TBL] [Abstract][Full Text] [Related]
8. Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection.
Burioni R; Mancini N; Carletti S; Perotti M; Grieco A; Canducci F; Varaldo PE; Clementi M
Virology; 2004 Oct; 327(2):242-8. PubMed ID: 15351212
[TBL] [Abstract][Full Text] [Related]
9. A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies.
Fournier C; Duverlie G; François C; Schnuriger A; Dedeurwaerder S; Brochot E; Capron D; Wychowski C; Thibault V; Castelain S
Virol J; 2007 Mar; 4():35. PubMed ID: 17397531
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus with a naturally occurring single amino-acid substitution in the E2 envelope protein escapes neutralization by naturally-induced and vaccine-induced antibodies.
Duan H; Struble E; Zhong L; Mihalik K; Major M; Zhang P; Feinstone S; Feigelstock D
Vaccine; 2010 Jun; 28(25):4138-44. PubMed ID: 20433800
[TBL] [Abstract][Full Text] [Related]
11. Predominance of antibodies to hepatitis C virus envelope proteins in various disease statuses of hepatitis C.
PodurI CD; Khanna A; Khundmiri SJ; Khaja MN; Kumar KS; Sugunan VS; Habibullah CM; Das MR
Acta Virol; 2001 Feb; 45(1):1-6. PubMed ID: 11394572
[TBL] [Abstract][Full Text] [Related]
12. Immunoreactivity of HCV/HBV epitopes displayed in an epitope-presenting system.
Chen Y; Xiong X; Liu X; Li J; Wen Y; Chen Y; Dai Q; Cao Z; Yu W
Mol Immunol; 2006 Feb; 43(5):436-42. PubMed ID: 16337486
[TBL] [Abstract][Full Text] [Related]
13. Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity.
Schofield DJ; Bartosch B; Shimizu YK; Allander T; Alter HJ; Emerson SU; Cosset FL; Purcell RH
Hepatology; 2005 Nov; 42(5):1055-62. PubMed ID: 16250048
[TBL] [Abstract][Full Text] [Related]
14. Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment.
Zibert A; Schreier E; Roggendorf M
Virology; 1995 Apr; 208(2):653-61. PubMed ID: 7538251
[TBL] [Abstract][Full Text] [Related]
15. Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus.
Johansson DX; Voisset C; Tarr AW; Aung M; Ball JK; Dubuisson J; Persson MA
Proc Natl Acad Sci U S A; 2007 Oct; 104(41):16269-74. PubMed ID: 17911260
[TBL] [Abstract][Full Text] [Related]
16. Characterization and mapping of a B-cell immunogenic domain in hepatitis C virus E2 glycoprotein using a yeast peptide library.
Mink MA; Benichou S; Madaule P; Tiollais P; Prince AM; Inchauspe G
Virology; 1994 Apr; 200(1):246-55. PubMed ID: 7510436
[TBL] [Abstract][Full Text] [Related]
17. Expression, purification and immunogenic characterization of hepatitis C virus recombinant E1E2 protein expressed by Pichia pastoris yeast.
Cai W; Su L; Liao Q; Ye L; Wu Y; Wu Z; She Y
Antiviral Res; 2010 Oct; 88(1):80-5. PubMed ID: 20691736
[TBL] [Abstract][Full Text] [Related]
18. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
[TBL] [Abstract][Full Text] [Related]
19. The hypervariable region 1 protein of hepatitis C virus broadly reactive with sera of patients with chronic hepatitis C has a similar amino acid sequence with the consensus sequence.
Watanabe K; Yoshioka K; Ito H; Ishigami M; Takagi K; Utsunomiya S; Kobayashi M; Kishimoto H; Yano M; Kakumu S
Virology; 1999 Nov; 264(1):153-8. PubMed ID: 10544140
[TBL] [Abstract][Full Text] [Related]
20. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.
Wong JA; Bhat R; Hockman D; Logan M; Chen C; Levin A; Frey SE; Belshe RB; Tyrrell DL; Law JL; Houghton M
J Virol; 2014 Dec; 88(24):14278-88. PubMed ID: 25275133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
